154 related articles for article (PubMed ID: 29063235)
1. Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy.
Zhao C; Li S; Zhao M; Zhu H; Zhu X
Arch Gynecol Obstet; 2018 Jan; 297(1):153-159. PubMed ID: 29063235
[TBL] [Abstract][Full Text] [Related]
2. Mismatch repair and treatment resistance in ovarian cancer.
Helleman J; van Staveren IL; Dinjens WN; van Kuijk PF; Ritstier K; Ewing PC; van der Burg ME; Stoter G; Berns EM
BMC Cancer; 2006 Jul; 6():201. PubMed ID: 16879751
[TBL] [Abstract][Full Text] [Related]
3. Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications.
Xiao X; Melton DW; Gourley C
Gynecol Oncol; 2014 Feb; 132(2):506-12. PubMed ID: 24333356
[TBL] [Abstract][Full Text] [Related]
4. Common variants in mismatch repair genes and risk of invasive ovarian cancer.
Song H; Ramus SJ; Quaye L; DiCioccio RA; Tyrer J; Lomas E; Shadforth D; Hogdall E; Hogdall C; McGuire V; Whittemore AS; Easton DF; Ponder BA; Kjaer SK; Pharoah PD; Gayther SA
Carcinogenesis; 2006 Nov; 27(11):2235-42. PubMed ID: 16774946
[TBL] [Abstract][Full Text] [Related]
5. Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients.
Mann A; Hogdall E; Ramus SJ; DiCioccio RA; Hogdall C; Quaye L; McGuire V; Whittemore AS; Shah M; Greenberg D; Easton DF; Ponder BA; Kjaer SK; Gayther SA; Thompson DJ; Pharoah PD; Song H
Eur J Cancer; 2008 Oct; 44(15):2259-65. PubMed ID: 18723338
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
8. MLH1 Is a Prognostic Biomarker for Serous Ovarian Cancer Treated With Platinum- and Taxane-based Chemotherapy.
Kawashima N; Yoshida H; Miwa M; Fujiwara K
Anticancer Res; 2019 Oct; 39(10):5505-5513. PubMed ID: 31570444
[TBL] [Abstract][Full Text] [Related]
9. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
10. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
[No Abstract] [Full Text] [Related]
11. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
12. Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6.
Hegan DC; Narayanan L; Jirik FR; Edelmann W; Liskay RM; Glazer PM
Carcinogenesis; 2006 Dec; 27(12):2402-8. PubMed ID: 16728433
[TBL] [Abstract][Full Text] [Related]
13. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
[TBL] [Abstract][Full Text] [Related]
14. DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer.
Dong X; Li Y; Hess KR; Abbruzzese JL; Li D
Oncologist; 2011; 16(1):61-70. PubMed ID: 21212431
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
Schmoeckel E; Hofmann S; Fromberger D; Rottmann M; Luthardt B; Burges A; Jeschke U; Kirchner T; Lax SF; Mayr D
Virchows Arch; 2019 May; 474(5):599-608. PubMed ID: 30734108
[TBL] [Abstract][Full Text] [Related]
16. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours.
Rudolph C; Melau C; Nielsen JE; Vile Jensen K; Liu D; Pena-Diaz J; Rajpert-De Meyts E; Rasmussen LJ; Jørgensen A
Cell Oncol (Dordr); 2017 Aug; 40(4):341-355. PubMed ID: 28536927
[TBL] [Abstract][Full Text] [Related]
17. Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance.
Scarpa M; Ruffolo C; Canal F; Scarpa M; Basato S; Erroi F; Fiorot A; Dall'Agnese L; Pozza A; Porzionato A; Castagliuolo I; Dei Tos AP; Bassi N; Castoro C
Oncotarget; 2015 Dec; 6(41):43472-82. PubMed ID: 26496037
[TBL] [Abstract][Full Text] [Related]
18. Tissue expression of MLH1, PMS2, MSH2, and MSH6 proteins and prognostic value of microsatellite instability in Wilms tumor: experience of 45 cases.
Diniz G; Aktas S; Cubuk C; Ortac R; Vergin C; Olgun N
Pediatr Hematol Oncol; 2013 May; 30(4):273-84. PubMed ID: 23570624
[TBL] [Abstract][Full Text] [Related]
19. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
Jin W; Wang LQ; Liu Y; Liu AJ
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
[No Abstract] [Full Text] [Related]
20. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Felsberg J; Thon N; Eigenbrod S; Hentschel B; Sabel MC; Westphal M; Schackert G; Kreth FW; Pietsch T; Löffler M; Weller M; Reifenberger G; Tonn JC;
Int J Cancer; 2011 Aug; 129(3):659-70. PubMed ID: 21425258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
